Beijing Increasepharm Safety and Efficacy Co., Ltd

Founded in 2017,  located in Peking University Medical Industrial Park in Zhongguancun Life Science Park, Changping District, with experimental area is nearly 2,000 m2, including ordinary and SPF animal rooms and related functional laboratories. The functional laboratory can meet requirements for detection of relevant indicators such as clinical examination, analysis, histopathology, cell biology, inhalation pharmacology and toxicology, and can also conduct pharmacodynamic and pharmcokinetic evaluation for various administration methods such as intravenous injection, intramuscular injection, subcutaneous injection, intraperitoneal injection, oral administration, dermal and pulmonary administration. Since its establishment, the company has developed into a national high-tech enterprise and a Zhongguancun high-tech enterprise. At present, the platform has undertaken 4 "National 13th Five-Year Major New Drug Development" projects.

Main business is drug screening, pharmacodynamic, pharmacokinetics, safety assessment and other research work. It has established two characteristic research platforms: nebulization research platform and new drug screening research platform. Among them, TCM nebulization research platform is the first CRO service platform for TCM nebulization pharmacodynamic and pharmacokinetic research in China, and was selected as the characteristic park project of the Zhongguancun Demonstration Zone in 2018. The company has solved the problem of multi-components and multi-target research of TCM, and on the basis of satisfying the evaluation of self-developed products, it can systematically provide a series of preclinical trial like drug screening evaluation, druggability research, action mechanism research and application and registration for chemical drug and TCM.